Assays on the anti-IL-13 antibody Tralokinumab reported a possible positive effect in a specific sub-group of patients with severe uncontrolled asthma and levels of serum dipeptidyl peptidase-4 (DPP-4) or periostin higher than the baseline median population [72]. The gene discussed is DPP4; the disease is asthma.